Key facts
- This page summarizes Charles K. Gayer's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 23 Dec 2025, 16:08.
Charles K. Gayer - 19 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)
- Reporting relationship
- President and CCO
- Issuer ticker
- BCRX
- Reported as of
- 19 Dec 2025
- Net transaction value
- +$286,851
- SEC form
- 4
- Accepted by SEC
- 23 Dec 2025, 16:08:40 UTC
- Prior SEC filing
- 19 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alane P. Barnes, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Charles K. Gayer filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 23 Dec 2025.
Change
- Previous filing in this sequence was filed on 19 Dec 2025.
- Current net transaction value: +$286,851.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001800110
Primary reporting owner
Gayer Charles K
- Relationship
- President and CCO
- Address
- 4505 EMPEROR BLVD., SUITE 200, DURHAM
- Signature
- /s/ Alane P. Barnes, by power of attorney
- Signature date
- 23 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCRX
transaction
Common Stock
Tax liability
- Transaction value
- $85,045
- Shares
- -11,477
- Change %
- -1.3%
- Price
- $7.41
- Shares after
- 878,350
- Date
- 19 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
BCRX
transaction
Common Stock
Options Exercise
- Transaction value
- $45,537
- Shares
- +14,142
- Change %
- +1.6%
- Price
- $3.22
- Shares after
- 892,492
- Date
- 22 Dec 2025
- Ownership
- Direct
BCRX
transaction
Common Stock
Options Exercise
- Transaction value
- $50,859
- Shares
- +10,091
- Change %
- +1.1%
- Price
- $5.04
- Shares after
- 902,583
- Date
- 22 Dec 2025
- Ownership
- Direct
BCRX
transaction
Common Stock
Options Exercise
- Transaction value
- $275,500
- Shares
- +50,000
- Change %
- +5.5%
- Price
- $5.51
- Shares after
- 952,583
- Date
- 22 Dec 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCRX
transaction
Derivative
Emp. Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -14,142
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 22 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,142
- Exercise price
- $3.22
- Footnotes
- F2
BCRX
transaction
Derivative
Emp. Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,091
- Change %
- -37%
- Price
- $0.000000
- Shares after
- 17,409
- Date
- 22 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,091
- Exercise price
- $5.04
- Footnotes
- F2
BCRX
transaction
Derivative
Emp. Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 22 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $5.51
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.
Footnote F2
The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.